| Inspire Pharmaceuticals announced patient enrollment is complete in three of its late-stage clinical trials. Inspire announced today that TIGER-2, the company’s second Phase 3 pivotal clinical trial with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis, has completed patient enrollment. Inspire also announced today that patient enrollment is complete in its Phase 3 clinical trial with PROLACRIA, the proposed U.S. tradename for diquafosol tetrasodium ophthalmic solution 2%, for the treatment of dry eye disease. :theflyonthewall.com |
